Cijauskaite E, Kazenaite E, Strainiene S, Sadauskaite G, Kurlinkus B. Nivolumab-induced tumour-like gastritis: A case report. World J Clin Cases 2023; 11(18): 4350-4359 [PMID: 37449232 DOI: 10.12998/wjcc.v11.i18.4350]
Corresponding Author of This Article
Sandra Strainiene, MD, Attending Doctor, Department of Internal Medicine and Surgery, Antakalnis Clinic, Antakalnis Street 59, Vilnius 10207, Lithuania. sandra.strainiene@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jun 26, 2023; 11(18): 4350-4359 Published online Jun 26, 2023. doi: 10.12998/wjcc.v11.i18.4350
Nivolumab-induced tumour-like gastritis: A case report
Elena Cijauskaite, Edita Kazenaite, Sandra Strainiene, Goda Sadauskaite, Benediktas Kurlinkus
Elena Cijauskaite, Faculty of Medicine, Vilnius University, Vilnius 01513, Lithuania
Edita Kazenaite, Goda Sadauskaite, Benediktas Kurlinkus, Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius 01513, Lithuania
Edita Kazenaite, Goda Sadauskaite, Benediktas Kurlinkus, Vilnius University Hospital Santaros Clinics, Center of Hepatology, Gastroenterology and Dietology, Vilnius 08661, Lithuania
Sandra Strainiene, Department of Internal Medicine and Surgery, Antakalnis Clinic, Vilnius 10207, Lithuania
Author contributions: Cijauskaite E wrote the original manuscript and reviewed the literature; Kurlinkus B was the gastroenterologist who followed-up the patient, obtained the patient’s informed consent and performed data extraction; Kurlinkus B, Strainiene S reviewed and edited the manuscript; Kurlinkus B, Sadauskaite G and Kazenaite E revised the manuscript for important intellectual content; All authors have read and approved the final manuscript.
Informed consent statement: The patient signed the institution's standard document for informed consent to use her health data for the purpose of this clinical case report.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sandra Strainiene, MD, Attending Doctor, Department of Internal Medicine and Surgery, Antakalnis Clinic, Antakalnis Street 59, Vilnius 10207, Lithuania. sandra.strainiene@gmail.com
Received: February 25, 2023 Peer-review started: February 25, 2023 First decision: April 11, 2023 Revised: April 23, 2023 Accepted: May 9, 2023 Article in press: May 9, 2023 Published online: June 26, 2023 Processing time: 121 Days and 14.1 Hours
Abstract
BACKGROUND
Immune checkpoint inhibitors are one of the modern treatment methods for advanced malignancies. However, this group of medications is also associated with various immune-related adverse events, such as colitis or pneumonitis. Immune checkpoint inhibitor-induced gastritis is a less common adverse event.
CASE SUMMARY
We describe a 64-year-old woman presenting with diarrhea, nausea, and discomfort in the upper abdominal region. The patient had a history of metastatic lung cancer, which was treated with nivolumab. During the first endoscopy, an infiltrating gastric tumour was suspected. Later, based on endoscopic, histological and radiological findings, nivolumab-induced gastritis was diagnosed. The patient was successfully treated with three courses of omeprazole.
CONCLUSION
As a consequence of the increased use of immune checkpoint inhibitors, a growing number of reported immune-related adverse events could be expected. The diagnosis of immune checkpoint inhibitor-induced gastritis should be considered when assessing a patient treated with nivolumab with upper gastrointestinal distress.
Core Tip: Nivolumab-induced gastritis is a less common immune-related adverse event of nivolumab. The most common symptoms include nausea, pain, diarrhea, loss of appetite, and weight loss. Esophagogastroduodenoscopy and biopsy are the most important diagnostic tools. In most cases, gastritis is treated with corticosteroids in combination with proton pump inhibitors. In our case, the patient was successfully treated with omeprazole monotherapy.
